Skin pigmentation and pharmacokinetics of melanotan-I in humans

Sydney O. Ugwu, James Blanchard, Robert T Dorr, Norman Levine, Christine Brooks, Mac E. Hadley, Mikel Aickin, Victor J Hruby

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

A comparative pharmacokinetic trial was performed with a superpotent synthetic melanotropic peptide, [Nle4-D-Phe7]-α-MSH1-13 (melanotan-I or MT-I) given by three routes of administration. Plasma levels were measured by RIA and tanning was quantitated using serial reflectometry. Doses of 0.16 mg kg-1 were administered intravenously (IV) and orally (PO), and doses from 0.08 to 0.21 mg kg-1 subcutaneously (SC), in a randomized crossover fashion to three male volunteers over five consecutive days for 2 weeks (ten doses). The results indicate that the SC dose is completely bioavailable compared to the IV dose. No detectable drug levels were observed following PO dosing. The plasma half-lives following SC dosing ranged from 0.07 to 0.79 h for the absorption phase and from 0.8 to 1.7 h for the β-phase. Clearance ranged from 0.12 to 0.19 L kg-1 h-1 and 3.9% or less of the dose was recovered in the urine. Side-effects were minimal, consisting of occasional gastrointestinal upset and facial flushing. Significant tanning of the forehead, arms, and neck was noted following IV or SC dosing. This effect peaked at 1 week following drug administration but was still present 3 weeks after completing the ten-dose regimen. It is concluded that SC administration is an efficacious method of delivering melanotan-I.

Original languageEnglish (US)
Pages (from-to)259-269
Number of pages11
JournalBiopharmaceutics and Drug Disposition
Volume18
Issue number3
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Tanning
Skin Pigmentation
Pharmacokinetics
Forehead
Pharmaceutical Preparations
Volunteers
Arm
Neck
Urine
Peptides

Keywords

  • humans
  • melanotan-I
  • pharmacokinetics
  • pigmentation

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Skin pigmentation and pharmacokinetics of melanotan-I in humans. / Ugwu, Sydney O.; Blanchard, James; Dorr, Robert T; Levine, Norman; Brooks, Christine; Hadley, Mac E.; Aickin, Mikel; Hruby, Victor J.

In: Biopharmaceutics and Drug Disposition, Vol. 18, No. 3, 1997, p. 259-269.

Research output: Contribution to journalArticle

Ugwu, Sydney O. ; Blanchard, James ; Dorr, Robert T ; Levine, Norman ; Brooks, Christine ; Hadley, Mac E. ; Aickin, Mikel ; Hruby, Victor J. / Skin pigmentation and pharmacokinetics of melanotan-I in humans. In: Biopharmaceutics and Drug Disposition. 1997 ; Vol. 18, No. 3. pp. 259-269.
@article{2049e970a7124427970e044c63771a45,
title = "Skin pigmentation and pharmacokinetics of melanotan-I in humans",
abstract = "A comparative pharmacokinetic trial was performed with a superpotent synthetic melanotropic peptide, [Nle4-D-Phe7]-α-MSH1-13 (melanotan-I or MT-I) given by three routes of administration. Plasma levels were measured by RIA and tanning was quantitated using serial reflectometry. Doses of 0.16 mg kg-1 were administered intravenously (IV) and orally (PO), and doses from 0.08 to 0.21 mg kg-1 subcutaneously (SC), in a randomized crossover fashion to three male volunteers over five consecutive days for 2 weeks (ten doses). The results indicate that the SC dose is completely bioavailable compared to the IV dose. No detectable drug levels were observed following PO dosing. The plasma half-lives following SC dosing ranged from 0.07 to 0.79 h for the absorption phase and from 0.8 to 1.7 h for the β-phase. Clearance ranged from 0.12 to 0.19 L kg-1 h-1 and 3.9{\%} or less of the dose was recovered in the urine. Side-effects were minimal, consisting of occasional gastrointestinal upset and facial flushing. Significant tanning of the forehead, arms, and neck was noted following IV or SC dosing. This effect peaked at 1 week following drug administration but was still present 3 weeks after completing the ten-dose regimen. It is concluded that SC administration is an efficacious method of delivering melanotan-I.",
keywords = "humans, melanotan-I, pharmacokinetics, pigmentation",
author = "Ugwu, {Sydney O.} and James Blanchard and Dorr, {Robert T} and Norman Levine and Christine Brooks and Hadley, {Mac E.} and Mikel Aickin and Hruby, {Victor J}",
year = "1997",
doi = "10.1002/(SICI)1099-081X(199704)18:3<259::AID-BDD20>3.0.CO;2-X",
language = "English (US)",
volume = "18",
pages = "259--269",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Skin pigmentation and pharmacokinetics of melanotan-I in humans

AU - Ugwu, Sydney O.

AU - Blanchard, James

AU - Dorr, Robert T

AU - Levine, Norman

AU - Brooks, Christine

AU - Hadley, Mac E.

AU - Aickin, Mikel

AU - Hruby, Victor J

PY - 1997

Y1 - 1997

N2 - A comparative pharmacokinetic trial was performed with a superpotent synthetic melanotropic peptide, [Nle4-D-Phe7]-α-MSH1-13 (melanotan-I or MT-I) given by three routes of administration. Plasma levels were measured by RIA and tanning was quantitated using serial reflectometry. Doses of 0.16 mg kg-1 were administered intravenously (IV) and orally (PO), and doses from 0.08 to 0.21 mg kg-1 subcutaneously (SC), in a randomized crossover fashion to three male volunteers over five consecutive days for 2 weeks (ten doses). The results indicate that the SC dose is completely bioavailable compared to the IV dose. No detectable drug levels were observed following PO dosing. The plasma half-lives following SC dosing ranged from 0.07 to 0.79 h for the absorption phase and from 0.8 to 1.7 h for the β-phase. Clearance ranged from 0.12 to 0.19 L kg-1 h-1 and 3.9% or less of the dose was recovered in the urine. Side-effects were minimal, consisting of occasional gastrointestinal upset and facial flushing. Significant tanning of the forehead, arms, and neck was noted following IV or SC dosing. This effect peaked at 1 week following drug administration but was still present 3 weeks after completing the ten-dose regimen. It is concluded that SC administration is an efficacious method of delivering melanotan-I.

AB - A comparative pharmacokinetic trial was performed with a superpotent synthetic melanotropic peptide, [Nle4-D-Phe7]-α-MSH1-13 (melanotan-I or MT-I) given by three routes of administration. Plasma levels were measured by RIA and tanning was quantitated using serial reflectometry. Doses of 0.16 mg kg-1 were administered intravenously (IV) and orally (PO), and doses from 0.08 to 0.21 mg kg-1 subcutaneously (SC), in a randomized crossover fashion to three male volunteers over five consecutive days for 2 weeks (ten doses). The results indicate that the SC dose is completely bioavailable compared to the IV dose. No detectable drug levels were observed following PO dosing. The plasma half-lives following SC dosing ranged from 0.07 to 0.79 h for the absorption phase and from 0.8 to 1.7 h for the β-phase. Clearance ranged from 0.12 to 0.19 L kg-1 h-1 and 3.9% or less of the dose was recovered in the urine. Side-effects were minimal, consisting of occasional gastrointestinal upset and facial flushing. Significant tanning of the forehead, arms, and neck was noted following IV or SC dosing. This effect peaked at 1 week following drug administration but was still present 3 weeks after completing the ten-dose regimen. It is concluded that SC administration is an efficacious method of delivering melanotan-I.

KW - humans

KW - melanotan-I

KW - pharmacokinetics

KW - pigmentation

UR - http://www.scopus.com/inward/record.url?scp=0030894458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030894458&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1099-081X(199704)18:3<259::AID-BDD20>3.0.CO;2-X

DO - 10.1002/(SICI)1099-081X(199704)18:3<259::AID-BDD20>3.0.CO;2-X

M3 - Article

C2 - 9113347

AN - SCOPUS:0030894458

VL - 18

SP - 259

EP - 269

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

IS - 3

ER -